<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180416039326N17</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-10</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Ketamine on Sedation in Bronchoscopy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effect of Three Different Ketamine doses on Quality of Sedation in Bronchoscopy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51454</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into three groups based on the table created by randomization software (Randomization and Minimization). Randomization is performed by an expert who is not a member of the research team, and each code will be stored in a sealed envelope until the end of the study. On the day of surgery, patients enter the operating room based on the numbers assigned to them, Blinding description: On the day of surgery, patients enter the operating room based on the numbers assigned to them. The medications will be prepared and injected by an anesthesiologist who has no role in collecting the information. An observer who is unaware of the grouping of patients and prescribes drugs records the results of the study.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Bronchoscopy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1 (The first group of Ketamine 0.2 mg/kg): Propofol 1.5 mg/kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml. Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol. If more sedation is needed, 0.5 mg / kg Propofol (5 mg/ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg/kg. Intervention 2: Intervention group 2 (the second group of ketamine 0.4 mg/kg): Propofol 1.5 mg / kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml.Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol.If more sedation is needed, 0.5 mg / kg Propofol (5 mg / ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg / kg. Intervention 3: Intervention group 3 (the third group of ketamine 0.5mg / kg): Propofol 1.5 mg / kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml.Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol.If more sedation is needed, 0.5 mg / kg Propofol (5 mg / ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg / kg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data include sedation and hemodynamic indices and complications in all three intervention groups after unidentifiable individuals can be shared.

When:
6 months after publication of paper

To whom:
Academic and medical researchers

Conditions:
Use for research and treatment purposes

Where to obtain:
Email of the person in charge of public accountability: Hamidshetabi@med.mui.ac.ir

How to obtain:
Upon request, it will be sent via email if available within a maximum of 1 month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamidraza Shetabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital; Sofe bolevard</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>hamidshetabi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamidraza Shetabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital; Sofe bolevard</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>hamidshetabi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who are candidates for Bronchoscopy
Being at the age over 18 years old
Patients whit ASA class 1 and 2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient disinclination
Mental disorders
History of chronic sedative drug use
Opioid and alcohol use disorders
History of any allergy to any medications use in the study
Take sedative or analgesics 24 hours before the procedure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1 (The first group of Ketamine 0.2 mg/kg): Propofol 1.5 mg/kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml. Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol. If more sedation is needed, 0.5 mg / kg Propofol (5 mg/ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg/kg.</i_keyword>
      <i_keyword>Intervention group 2 (the second group of ketamine 0.4 mg/kg): Propofol 1.5 mg / kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml.Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol.If more sedation is needed, 0.5 mg / kg Propofol (5 mg / ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg / kg.</i_keyword>
      <i_keyword>Intervention group 3 (the third group of ketamine 0.5mg / kg): Propofol 1.5 mg / kg is drawn into the pump syringe and according to the grouping, Ketamine is added to Propofol and the syringe volume is reduced to 15 ml.Sedation is started by gradual bolus injection of 50-100mcg / kg Propofol based on pump syringe Reaching the desired sedation level 3 based on Ramsey Continuation of sedation continues at an infusion rate of 50-100mcg / kg Propofol.If more sedation is needed, 0.5 mg / kg Propofol (5 mg / ml) will be injected in all three groups. If you feel pain during the procedure in all three groups of Fentanyl 1mcg / kg and if you feel pain in recovery, Apotel will be used at a dose of 15 mg / kg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation level based on Ramsay score. Timepoint: During the operation every 5 minutes and then in recovery room every 15 minutes, until recovery from recovery room. Method of measurement: questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart Rate. Timepoint: Before the operation, During the operation every 5 minutes and then in recovery every 15 minutes, until recovery from recovery. Method of measurement: monitoring.</sec_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: Before the operation, During the operation every 5 minutes and then in recovery every 15 minutes, until recovery from recovery. Method of measurement: monitoring.</sec_outcome>
      <sec_outcome>Diastolic blood pressure. Timepoint: Before the operation, During the operation every 5 minutes and then in recovery every 15 minutes, until recovery from recovery. Method of measurement: monitoring.</sec_outcome>
      <sec_outcome>Mean Atrial Pressure. Timepoint: Before the operation, During the operation every 5 minutes and then in  recovery every 15 minutes, until recovery from recovery. Method of measurement: monitoring.</sec_outcome>
      <sec_outcome>Percentage of arterial oxygen saturation. Timepoint: Before the operation, During the operation every 5 minutes and then in recovery every 15 minutes, until recovery from recovery. Method of measurement: monitoring.</sec_outcome>
      <sec_outcome>Complications during the procedure (hypo tension, hypertension, tachycardia, bradycardia, pain ...). Timepoint: During the operation every 5 minutes  minutes. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Complications in recovery (vomiting nausea ...). Timepoint: in recovery every 15 minutes, until recovery from recovery. Method of measurement: questionnaire.</sec_outcome>
      <sec_outcome>Duration of stay in recovery. Timepoint: per minutes. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-09</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Al-Zahra Hospital; Sofe bolevard Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
